Assessing the risk of clinical and pathologic factors for relapse of borderline ovarian tumours

Abstract The objective of this study was to identify clinical and pathologic factors that are significant to relapse in borderline ovarian tumours (BOT). All patients with BOTs from 1997 to 2012 in our institute were identified. 115 patients were included in the study. The Cox proportional hazards model was used to identify significant factors. The median age was 42 years (range 14–85 years). The majority of the patients were at FIGO stage I (88.7%), and most of the patients had mucinous histology (66.1%), reflecting the predominant distribution of mucinous BOTs in East Asia. The median follow-up was 3.3 years (range 0–4.1 years). Twelve patients (10.4%) relapsed and two died consequently. Advanced stage, invasive implants and restaging surgery were significant factors of recurrence. Serous tumours had slightly higher risk than mucinous tumours, but the difference was not significant. As the study was performed in an area where mucinous BOTs are predominant, the results may complement current literature on BOT management.

[1]  R. Kurman,et al.  WHO classification of tumours of female reproductive organs , 2014 .

[2]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[3]  Jeong-Won Lee,et al.  Endocervical-Like versus Intestinal-Type Mucinous Borderline Ovarian Tumors: A Large Retrospective Series Focusing on the Clinicopathologic Characteristics , 2013, Gynecologic and Obstetric Investigation.

[4]  L. Woelber,et al.  Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT) , 2013, Journal of Ovarian Research.

[5]  J. Nam,et al.  Fertility-Sparing Surgery for Young Women with Early-Stage Epithelial Ovarian Cancer , 2013, Gynecologic and Obstetric Investigation.

[6]  T. Fehm,et al.  Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. , 2013, European journal of cancer.

[7]  J. Raduà,et al.  Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor , 2013, World Journal of Surgical Oncology.

[8]  Jeong-Won Lee,et al.  Histologic distribution of borderline ovarian tumors worldwide: a systematic review , 2013, Journal of gynecologic oncology.

[9]  E. Darai,et al.  Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. , 2012, The Lancet. Oncology.

[10]  P. Morice,et al.  Prognostic value of lymph node involvement in ovarian serous borderline tumors. , 2011, American journal of obstetrics and gynecology.

[11]  R. Barakat,et al.  Risk factors for recurrence of ovarian borderline tumors. , 2011, Gynecologic oncology.

[12]  P. Ghatage,et al.  Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre , 2011, Archives of Gynecology and Obstetrics.

[13]  M. Andujar,et al.  Serous and mucinous borderline ovarian tumors: are there real differences between these two entities? , 2010, European journal of obstetrics, gynecology, and reproductive biology.

[14]  F. Landoni,et al.  The role of restaging borderline ovarian tumors: single institution experience and review of the literature. , 2010, Gynecologic oncology.

[15]  J. H. Price,et al.  Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype , 2010, Journal of Clinical Pathology.

[16]  Chi-Ju Yeh,et al.  Prognostic factors predicting recurrence in borderline ovarian tumors. , 2009, Gynecologic oncology.

[17]  Yong-Man Kim,et al.  Surgical management of borderline ovarian tumors: The role of fertility-sparing surgery. , 2009, Gynecologic oncology.

[18]  A. Gown,et al.  Ovarian Atypical Proliferative (Borderline) Mucinous Tumors: Gastrointestinal and Seromucinous (Endocervical-Like) Types are Immunophenotypically Distinctive , 2006, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[19]  J. McKenney,et al.  Ovarian Serous Tumors of Low Malignant Potential (Borderline Tumors): Outcome-Based Study of 276 Patients With Long-Term (≥5-Year) Follow-Up , 2005, The American journal of surgical pathology.

[20]  W. R. Hart Borderline epithelial tumors of the ovary , 2005, Modern Pathology.

[21]  E. Daraï,et al.  Restaging surgery for women with borderline ovarian tumors , 2004, Cancer.

[22]  C. Haie-meder,et al.  Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  J. Prat,et al.  Serous Borderline Tumors of the Ovary: A Long-Term Follow-Up Study of 137 Cases, Including 18 With a Micropapillary Pattern and 20 With Microinvasion , 2002, The American journal of surgical pathology.

[24]  A. Malpica,et al.  Micropapillary and Cribriform Patterns in Ovarian Serous Tumors of Low Malignant Potential: A Study of 99 Advanced Stage Cases , 2002, The American journal of surgical pathology.

[25]  E. Trimble,et al.  Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. , 2002, Gynecologic oncology.

[26]  C. Mangioni,et al.  Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Lissoni,et al.  [Comparison of methods for monitoring young women with stage I borderline ovarian tumor after conservative surgery]. , 2001, Minerva Ginecologica.

[28]  P. Morice,et al.  Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. , 2001, Fertility and sterility.

[29]  B. Davidson,et al.  CA 125 measurement and ultrasonography in borderline tumors of the ovary. , 2000, American journal of obstetrics and gynecology.

[30]  H. Hollema,et al.  Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. , 2000, Gynecologic oncology.

[31]  D. Gal,et al.  Contemporary surgical management of borderline ovarian tumors: a survey of the Society of Gynecologic Oncologists. , 2000, Gynecologic oncology.

[32]  D. Gershenson Contemporary treatment of borderline ovarian tumors. , 1999, Cancer investigation.

[33]  R. Barakat,et al.  Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. , 1995, Gynecologic oncology.

[34]  V. Abeler,et al.  Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. , 1993, Gynecologic oncology.

[35]  J. Nam,et al.  Ovarian Tumors of Low Malignant Potential , 1993 .

[36]  I. Vergote,et al.  Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary , 1992, International Journal of Gynecologic Cancer.

[37]  E. W. Sonnendecker,et al.  Epithelial ovarian tumours of low malignant potential. , 1986, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.